20.60
0.00%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About RBC Bioscience
Its shares trade on Taipei Exchange under the ticker 6848.TWO. It has been listed since 25 October 2021. In the fiscal year to 31 December 2024, it reported revenue of TWD 205.2m and net income of TWD 21.6m. At that date it held total assets of TWD 763.9m and shareholders' equity of TWD 249.3m.
RBC Bioscience Corp. manufactures reagents and devices for life science and molecular diagnosis. The company is headquartered in Taipei, New Taipei. The company went IPO on 2021-10-25. The firm's products are mainly divided into instruments and reagents. The instruments are equipped with ultraviolet sterilization system to improve the quality of nucleic acid purification, and the disposable individual reagent strips and tips can be used with different built-in control programs to achieve different types of nucleic acid extraction. The firm developed and produced a variety of nucleic acid purification reagents with cellulose-embedded magnetic beads, which can improve the purity of nucleic acid, and therefore can be used to purify deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) for blood, bacteria, viruses and forensic examinations for future diagnosis, prevention, tracking, treatment of diseases or identification.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 25 Oct 2021
- Website
- rbcbioscience.com ↗
Leadership
Pay as last reported
- Mr. Mingwei ZhuoChairman of the Board, General Manager, since 2006
- Ms. Sulan FangFinance Manager
- Mr. Yanliang ChenDeputy General Manager-Manufacturing Division
- Mr. Kexin ZhanDeputy General Manager-Management Division
- Mr. Kaimin WangDirector
- Ms. Wanru XieDirector
- Mr. Shouxiong BaiIndependent Director
- Mr. Jianping LinIndependent Director
- Chuanhui WuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis in Taipei, Taiwan.
- The company's instruments feature ultraviolet sterilization for high-quality nucleic acid purification.
- RBC Bioscience developed cellulose-embedded magnetic bead reagents for improved DNA and RNA purity.
Weaknesses
- RBC Bioscience Corp's products are limited to nucleic acid purification with no mention of other life science applications.
- The company's business is concentrated in the Health Care sector without diversification into other industries.
- RBC Bioscience's IPO was on 25 October 2021, showing limited market history.
Opportunities
- RBC Bioscience Corp can expand its nucleic acid purification reagents for forensic examinations and disease tracking in Taiwan.
- The company's instruments with ultraviolet sterilization can be marketed to global health care providers.
- RBC Bioscience's reagents for DNA and RNA purification can be used in blood and virus testing worldwide.
Threats
- RBC Bioscience Corp faces competition from other life science tool manufacturers in Taiwan.
- The company's reliance on nucleic acid purification may limit growth in other health care segments.
- RBC Bioscience's products are not yet available in international markets beyond Taiwan.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.